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Complex sphingolipids are essential structural components of intestinal membranes, providing protection and integrity to the
intestinal mucosa and regulating intestinal absorption processes. The role of sphingolipid signaling has been established in
numerous cellular events, including intestinal cell survival, growth, differentiation, and apoptosis. A significant body of knowledge
demonstrates that intestinal sphingolipids play a crucial role, as such and through their signaling pathways, in immunity and
inflammatory disorders. In this review, we report on and discuss the current knowledge on the metabolism, signaling, and
functional implications of sphingolipids in inflammatory bowel disease (IBD), focusing on the different aspects of sphingolipid
actions on inflammatory responses and on the potential of sphingolipid-targeted molecules as anti-IBD therapeutic agents.
1. Introduction
Complex sphingolipids, including sphingomyelin (SM) and
glycosphingolipids (GSLs), are essential components of
intestinal membranes, providing protection and integrity to
the mucosa and regulating intestinal digestion and absorp-
tion processes. As in other organs, in the intestine, simple
sphingolipids/sphingoids, which are intermediates of sphin-
golipidmetabolism, are involved in the control of key cellular
events such as survival, proliferation, differentiation, and
apoptosis. Indeed, the metabolism of complex sphingolipid
includes enzymes involved in different signaling pathways,
which lead to the formation of bioactivemolecules, including
ceramide (Cer) and sphingosine (Sph), as well as their 1-
phosphorylated derivatives ceramide-1-phosphate (C1P) and
sphingosine-1-phosphate (S1P).
The role and impact of sphingolipids and sphingolipid-
mediated signaling emerged in their relevance in intestinal
disorders, when aberrations in their metabolism lead to an
altered sphingolipid homeostasis. Herein, we review our cur-
rent knowledge on the impact of sphingolipid disequilibrium
on intestinal inflammation, focusing on inflammatory bowel
disease (IBD).
2. Inflammatory Bowel Disease
The term IBD encompasses a group of common chronic
inflammatory disorders affecting the gastrointestinal tract [1].
The major types of IBD are Crohn’s disease (CD) and ulcera-
tive colitis (UC). Despite some overlapping clinical features,
these diseases are characterized by distinct inflammatory pro-
files, gutmicrobiota composition, and symptomatology [2, 3].
CD potentially affects any portion of the alimentary tract and
is characterized by a discontinuous and ulcerous transmural
inflammation, associated with complications (e.g., intestinal
granulomas, obstructions, abscesses, strictures, and fistulas)
[3]. In UC, a continuous inflammation involves only the
superficial layers of the intestinal mucosa and is localized
to regions of the gut most highly colonized by bacteria,
specifically at the rectum and moving proximally along the
large bowel [4].
The pathogenesis of IBD is complex (Figure 1) and for
many aspects remains unclear. The general hypothesis is that
IBD develops as a result of a persistent alteration of intestinal
homeostasis, leading to a perturbation of the balance between
the intestinal mucosa and the gut microbiome [1]. Diverse
factors, such as genetic, environmental, and immunologic
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Figure 1: The pathogenesis of IBD. Genetic, microbial, and environmental factors participate to disrupt the intestinal barrier. The defective
mucosal integrity starts a complex vicious cycle that leads to, enhances, and perpetuates IBD.
variations, participate to and influence the onset and reac-
tivation of this disease [4, 5]. There is compelling evidence
that an inherited/acquired genetic predisposition that leads to
barrier disruption and overreaction of the mucosal immune
responses to enteric/environmental antigens are major fac-
tors contributing to the pathogenesis of IBD [6–8]. The
dysregulated reaction of the mucosal immunity to normal
intestinal microfloramay be induced by defects in the epithe-
lial barrier (increased intestinal permeability), adherence of
bacteria, or expression of the “defensins” proteins.
The interaction among intestinal epithelial cells (IECs),
intestinal microbes, and local immune cells plays a cru-
cial role in the maintenance of the intestinal homeostasis
and is disrupted in IBD, leading to overreaction of the
mucosal immune response to normal intestinal microflora.
Indeed, a common histopathological feature of IBD is an
excessive immune activation, characterized by an exagger-
ated infiltration of mast cells, monocytes/macrophages, and
polymorphonuclear leukocytes into the intestinal epithelium.
This overabundance of immune cells is accompanied by
continuous and dramatic production of proinflammatory
stimuli, including cytokines, growth factors, and adhesion
molecules, as well as of inflammatory mediators (especially
those of the eicosanoid family) and reactive oxygen species
(ROS) [9, 10]. All this results in the development of a severe
and pervasive inflammation that promotes and exacerbates
IBD.
3. Intestinal Sphingolipid Equilibrium
The small intestine is lined by a single layer of self-renewing
IECs, which cover the surface of fingers-like projections
called villi, and that of flask-like structures around the base
of villi called crypts.The large intestine does not contain villi.
Complex sphingolipids are present throughout the intestinal
tract, with preferential localization in the apical membrane
of polarized IECs, endowing its architecture with enhanced
stability and digestive/absorptive capacity. Enterocytes of the
small intestine are characterized by the selective abundance
of SM and glucosylceramide (GlcCer), whose levels account
for more than twofold that of the colonic mucosa and about
40% of total lipids [11]. The high content of sphingolipids
in the small intestine is associated with selective enrichment
and localization of several species in the apical membrane
of the absorptive villous cells, which parallels the continuous
process of mucosal cell differentiation throughout the crypt-
villus axis [12]. Indeed, individual sphingolipids are differ-
ently distributed in villus and crypt cells, higher amounts
of Sph, GlcCer, and GM3 being present in villi and Cer,
trihexosyl-Cer, and GD3 ganglioside in crypts [13].















































Figure 2: Metabolism and balance of intestinal sphingolipids in physiological conditions and IBD. (a) Interconnected pathways of intestinal
sphingolipid metabolism. (b) In the healthy state, intestinal sphingolipids are in a “functional equilibrium” (left); in the inflamed state of IBD,
an unbalance of this equilibrium occurs, favoring the inflammatory disease (right).
Sphingolipids have rapid turnover, and their levels are
controlled by the balance between synthesis and degrada-
tion. As in most cells, the overall metabolism of intestinal
sphingolipids is complex and intricate (Figure 2(a)) and
involves multiple enzymes, also present in different isoforms
and subcellular districts. Sphingolipids of the intestinal tract
are synthesized via either “de novo pathway” (initiated by
serine condensation with palmitoyl-CoA through serine
palmitoyltransferase) or the “salvage pathway” (the recycling
of free Sph derived from sphingolipid catabolism). In both
pathways, the action of ceramide synthase (CerS) is required
to produce Cer, and five of the six known isoforms of
CerS are expressed in the intestinal mucosal cells [11]. The
newly formed Cer in the endoplasmic reticulum is then
transferred to the Golgi apparatus through either the pro-
tein (CERT) mediated transport (for SM biosynthesis) or a
vesicle-mediated route (for both SM and GSLs formation)
[14]. Two types of SM synthases (SMS) (SMS1 and SMS2) have
been identified and cloned in the intestinal cells. SMS1 resides
in the Golgi whereas SMS2 mainly presents at the plasma
membrane. GlcCer synthase is highly expressed in the small
and large intestine, rendering GlcCer the major intestinal
GSL. GlcCer is also the substrate of galactosyltransferase and
then of sialyltransferase abundant in villous cells, to provide
lactosyl-Cer and GM3 [11].
Concerning sphingolipid catabolism, the intestine is
characterized by the ability to hydrolyze both endogenous
and exogenous (dietary-derived) sphingolipids. Intestinal SM
degradation, catalyzed by sphingomyelinase (SMase) and
ceramidase (CDase), has been the object of different studies.
SMase and CDase can act both inside mucosal cells and
as ectoenzymes, being present either in the intracellular
environment or on the outer surface of the cell membrane or
in the intestinal lumen. So far, three isoforms of SMase, acid
(A-SMase), neutral (N-SMase), and alkaline (Alk-SMase), are
figured out in the intestine with different compartmentaliza-
tion. A-SMase (and in minor amounts N-SMase) is mainly
localized in highly proliferating crypt cells, particularly of the
proximal intestine, and appears to be mainly involved in the
hydrolysis of SM internalized by endocytosis [11]. Alk-SMase
is found preferentially in the middle part of the intestine,
primarily at the brush border, and is recognized as the major
enzyme for dietary SM digestion, even if it is also able to
hydrolyze the plasma membrane SM of mucosal cells [15].
Besides SMase, also CDase is present in the intestine as
three isoforms, including the neutral (N-CDase), the alkaline,
and the acid one, the former exhibiting the highest catalytic
activity in the presence of bile salts [16]. Although direct
absorption of SM andCer in humans cannot be excluded [17],
there is ample evidence that free Sph, produced through Alk-
SMase andN-CDase digestion, is themajor absorbed product
of dietary SM. Once internalized into the enterocytes, Sph
is rapidly metabolized, mainly to S1P by sphingosine kinase
(SphK). In the small intestine of mice, the total SphK activity
was shown to be about twofold that of colon, and SphK1
contributed approximately 40% to the total kinase activity in
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small intestine, whereas it was the prevalent isoform in colon
[18]. Interestingly, an unidentified SphK with high activity
toward phytosphingosine was reported to be the prominent
SphK in the small intestine [18]. S1P lyase that degrades S1P
to phosphoethanolamine and palmitaldehyde is expressed at
high levels in the intestinal mucosa [19], most probably to
reduce the level of S1P (and Sph) derived from the digestion
of dietary sphingolipids.
This intricate network of metabolic reactions leads to the
physiological presence of multiple sphingolipid molecules,
which play fundamental roles in the digestive, absorptive,
protective, and defense properties of the intestine.
4. Aberrant Sphingolipid Metabolism
Leads to a (Proinflammatory) Sphingolipid
Pattern in IBD
There is compelling evidence that dysregulated production
of several sphingolipid molecules occurs along with IBD and
contributes as a major factor to the pathogenesis and main-
tenance of this disorder. Indeed, sphingolipid metabolism
and the cellular level/distribution of different sphingolipids
exhibit significant changes in IBD. These variations not
only alter the healthy sphingolipid equilibrium essential
for intestinal functions, but also implicate cell-signaling
responses that precipitate the pathology.
Accumulating pieces of evidence demonstrate that a sig-
nificant increase in some sphingolipid species, including SM,
Cer, and the sphingoids mediators C1P and S1P, is associated
with IBD and is counterbalanced by the decrease of other
molecules, especially GlcCer and GM3 (Figure 2(b)). Indeed,
SM and Cer are significantly increased in a colitis mouse
model [20], as well as in feces of animals with dextran sulfate
sodium- (DSS-) induced colitis (an experimental model of
IBD) [21]. In agreement, and of relevance, high levels of SM
and Cer were reported in the ileum from CD patients [22],
providing evidence that SM and Cer generation accompanies
and possibly aggravates chronic intestinal inflammation.
Different enzymatic alterations appear to contribute to the
increased SM in IBD. First, a decrease in Alk-SMase activity
was demonstrated in human chronic colitis [23], possibly
acting as a key mechanism to induce SM accumulation.
In addition, colon samples from mice with a DSS-induced
IBD exhibit downregulation of N-SMase, and, of relevance,
concomitant upregulation of SMS2 [20].
Both the increase of glucocerebrosidase (responsible for
GlcCer hydrolysis to Cer) and CerS activation were found in
IBD and were suggested to be responsible for Cer elevation
[24]. Moreover, in colon cancer cells, tumor necrosis factor
𝛼 (TNF-𝛼), a proinflammatory cytokine that plays a pivotal
role in IBD, was shown to upregulate the de novo pathway
of sphingolipid biosynthesis [25], and it is conceivable that
this effect could contribute to Cer and SM accumulation
in IBD. A further study on mice revealed that also Sph
level is elevated in colon inflammation [26], most likely as
a consequence of the increased expression and activity of
N-CDase. Indeed, it was shown that N-CDase expression
and activity increase in colon epithelium of mice during
DSS-induced IBD [26]. On the contrary, it was shown that
the ganglioside content of inflamed intestinal mucosa is
significantly decreased [27]. Whether enhanced catabolism
of gangliosides and/or decreased biosynthesis from Cer
are responsible for ganglioside depletion in IBD remains
unknown. In a rat model of intestinal inflammation, the 1-
phosphorylated forms ofCer (C1P) and Sph (S1P)were shown
to increase in a time-dependent fashion with inflammation
[28]. The increase of S1P levels is of particular relevance in
IBD colon and occurs not only in the intestine but also in
blood, as a consequence of the enhanced expression of SphK1
[29]. On the contrary, the deficiency of SphK2 was shown to
significantly reduce IBD severity [30].
It is unknown whether alterations of sphingolipid
metabolism precede the onset of the chronic inflamed state of
IBD, or the inflammatory condition induces them. It appears
plausible that both conditions are operative, sphingolipid
aberrations favoring and on their turn being favored by the
IBD condition.
5. Sphingolipid Unbalance:
A Multiarmed Force of IBD
IBD hasmany tiers of initiation, progression, and evolvement
to reach the summit of intestinal damage. The multiple and
significant alterations of sphingolipids and bioactive sphin-
goids level associated with IBD result in a variety of effects
on these tightly interrelated tiers, including the epithelial
barrier integrity, immune cell targeting and signaling, and
innate/adaptive immune responses (Figure 3).
5.1. Sphingolipid Alterations Favor the Disruption of the Intesti-
nal Barrier in IBD. Acritical function of the intestinal epithe-
lium is to form a selective permeable barrier that allows the
appropriate absorption of nutrients but limits the permeation
of noxious agents, such as pathogens, toxins, and antigens,
from the luminal environment [31]. This specialized per-
meable barrier is achieved by different structures, including
mucus and intercellular tight junctions (TJs), which control
luminal molecules-intestinal cells interactions and paracel-
lular permeability [32]. It is recognized that the disruption
of the intestinal TJ barrier, followed by the permeation of
luminal noxious agents, and perturbation of the mucosal
immune system and inflammation, acts as a key trigger
of IBD development [33]. IBD patients exhibit increased
intestinal permeability, which favors bacterial/viral infections
and thus onset/relapse of IBD. Observations on IBD patients
pointed out the role of bacteria in this inflammation, and
antibiotics were found to be effective in some patients with
IBD [34]. In agreement, most mousemodels of colitis require
intestinal bacteria to occur [35].
It is noteworthy that the intestinal permeability is also
influenced by the content and pattern of IEC sphingolipids
(Figure 3). Both Sph and its N-acylated derivative Cer are
elevated in IBD and emerged as antibarrier effectors (Fig-
ure 3(a)). By using fumonisin B1 (a fungal inhibitor of CerS
that leads to Sph accumulation and depletion of complex
sphingolipids), it was found that the toxin induces a primary
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Figure 3: Inflammatory roles of sphingolipids in IBD. (a) Simple sphingolipids (C1P, Cer, and S1P) act as potent proinflammatorymessengers,
favoring and exacerbating the IBD condition. (b) Complex sphingolipids (SM and GSLs) exert several anti-inflammatory effects.
defect in barrier function, increasing intestinal epithelial
permeability [36]. In addition, fumonisin B1 treatment in pigs
resulted in a significant increase of intestinal colonization
by pathogenic E. coli [37]. As far as Cer is concerned, it is
recognized that it selectively accumulates in cholesterol- and
sphingolipid-enriched membrane microdomains, which also
include TJs [33]. The packing of Cer in these microdomains
alters the lipid rafts composition, contributing to a disturbed
barrier function [38]. In agreement, the neutralization of cell
surface Cer prevented the loss of barrier function induced by
platelet-activating factor (PAF) [38].
Opposite to the negative effects of Sph and Cer at the
intestinal barrier, GSLs (gangliosides and GlcCer), enriched
on the luminal membrane of enterocytes, protect intestinal
mucosa from injuries induced by bile salts, gastric juice acid-
ity, and toxins/pathogens entry (Figure 3(b)). In particular,
through their negative charge, gangliosides such as GM1 and
GM3 are able to bind, and then inactivate, the toxins of
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Vibrio cholerae, E. coli, and Shigella [39–41]. Of interest, these
antibacterial effects can be improved by dietary gangliosides.
A recent in vivo study on lipopolysaccharide- (LPS-) induced
inflammation revealed that dietary gangliosides inhibit the
degradation of gut occludin, a major protein of intestinal TJs
[42], implicating them in the intestinal barrier properties. In
addition, dietary GlcCer was shown to induce the expression
of claudin-1, thus improving TJ properties [43].
Overall, it emerges that the significant reduction of GSLs,
especially GM3 and GlcCer, associated with the concomitant
elevation of Sph and Cer, markedly concurs to alter the
permeability properties of the intestinal epithelium in IBD.
5.2. Sphingolipids and Cytokine Networks in IBD. A well-
recognized feature of IBD is the overproduction of proinflam-
matory cytokines,mainly represented by TNF-𝛼, interleukin-
(IL-) 6, and IFN-𝛾 [44]. In the IBD intestine, excess of
macrophages and subpopulations of macrophages not nor-
mally present in the lamina propria of the intestine is present,
indicating ongoing recruitment to the inflamed bowel. The
abundance and activation of these innate and adaptive
immune cells in the intestinalmucosa result in increased local
levels of proinflammatory mediators [44]. In active IBD, an
elevated expression of TNF-𝛼 occurs, consequent to the high
density of TNF-𝛼 producing cells, especially macrophages
within the lamina propria [45]. The high level of TNF-𝛼
contributes to the inflammatory tissue damage, by impairing
the integrity of epithelial and endothelial membranes and
increasing the recruitment of inflammatory cells [46].
Different studies implicate a strong network connection
between cytokines and different sphingolipids as critical
in the regulation of inflammatory pathways and immune
reactions in IBD. In this connection, SphK1 emerged as key
actor, being activated by several cytokines, among which
TNF-𝛼 plays a prominent role [47]. SphK1 acts as important
mediator of various cellular processes in IBD, most likely
downstream of TNF-𝛼 and upstream of cyclooxygenase-
(COX-) 2. Indeed, in a DSS-induced colitis model, Snider
et al. [29] reported that SphK1 depletion failed to induce
colonic COX-2 and the consequent prostaglandin (PG)E2
production, which contributes to the exacerbation of the
inflammatory colon damage. In the same study, it was
reported that S1P produced by SphK1 is able to promote
neutrophil infiltration into the crypts and lamina propria
of the colon [29]. Thus, S1P emerged as a chemoattractant
for granulocytes in the inflamed intestine either directly
or through the production of other local chemoattractants,
and in both cases the SphK1/S1P pathway promoted the
tissue inflammatory reaction. In a follow-up study, the same
group provided further insights into the distinct roles of
hematopoietic (bone marrow-derived) and extrahematopoi-
etic (intestinal) SphK1/S1P pathway in the pathogenesis
of IBD [48]. Hematopoietic-derived SphK1 was found as
major contributor to circulating S1P, which, on its turn,
was implicated in lymphocyte egress from the spleen, and
circulating neutrophil increase [48]. This led to a high
neutrophil/lymphocyte ratio, a steady indicator of systemic
inflammation in colitis [49]. In addition, both hematopoietic
and extrahematopoietic S1P were involved in the increased
expression of IL-1𝛽 and IL-6, aswell as in the phosphorylation
of STAT3, a tightly regulated transcription factor implicated
in chronic colitis associated cancer [48, 50]. As far as the
extrahematopoietic SphK1/S1P is concerned, this was shown
to be essential for the autocrine induction of COX-2 in the
colon tissue [48].
Although the absence of SphK1 was protective against
DSS-inducedcolitis [51], SphK2depletion resulted in enhanced
proliferation and proinflammatory cytokine production, and
thus IBD progression [30, 51]. Indeed, knockout mice for
SphK2 were shown to develop more severely damaged and
necrotic colonic mucosa, with pronounced loss of crypt
structures and extensive infiltration of inflammatory cells,
eosinophils, and neutrophils [30]. In SphK2(−/−) mice,
mesenteric lymphnode cells overproduced proautoimmunity
cytokines, and T-cells induced more rapid and robust IBD
in scid recipients which enhanced the pathological pheno-
types of colitis severity, suggesting that SphK2 negatively
modulates inflammatory responses and significantly reduces
IBD severity [30]. These findings support the hypothesis that
therapeutic enhancement of SphK2 activity and/or depletion
of SphK1 may be effective treatments for the exuberating
inflammation of IBD.
Different reports demonstrate that Cer generated by
SMase is able to exert powerful effects, even opposite, on
IBD cytokine production and signaling. In the inflammatory
processes of the gastrointestinal tract, the infiltration of
inflammatory cells into the intestinal mucosa leads to a
marked increase of IL-1𝛽 and then to NF-𝜅B activation [44].
Both IL-1𝛽 and NF-𝜅B exert detrimental effects, by inducing
the expression of proinflammatorymediators that orchestrate
and sustain the inflammatory response, finally determining
tissue damage. A study by Homaidan et al. [52] on murine
IECs demonstrated that IL-1𝛽 activates N-SMase through
NF-𝜅B, thus inducing significant accumulation of Cer. Cer
was found to mimic IL-1𝛽 in enhancing PGE2 generation
through COX-2 induction and by promoting the rise of
chloride and water secretion, a typical alteration of IBD
patients [52, 53]. Cer generated by N-SMase was shown to
induce apoptosis in human colon HT-29 cells, through NF-
𝜅B activation and IL-8 expression [54]. In addition, also the
A-SMase-derived Cer was apoptotic, but by activating NF-
𝜅B on distinct 𝜅B complexes [54]. Besides IL-1𝛽 and TNF-
𝛼, also LPS induces the release of inflammatory cytokines
from monocyte/macrophages via A-SMase activation, and
Cer generation leads to the expression of a variety of genes
and results in inflammatory responses [55].
It is recognized that Cer can exert opposite effects
depending on its enzymatic origin and/or site of production
[56]. Indeed, opposite to the proinflammatory effects of Cer
produced by N- and A-SMase in the intestine, Cer gener-
ated by Alk-SMase was shown to promote intestinal anti-
inflammatory pathways. In fact, the conversion of the apical
membrane SM to Cer by intestinal Alk-SMase was found to
inhibit cholera toxin endocytosis and host cells intoxication
[57]. Further support for the anti-inflammatory action of
intestinal Alk-SMase was provided by a report showing that,
in rats with DSS-induced colitis, the intrarectal instillation of
Alk-SMase induced TNF-𝛼 inhibition, significantly reduced
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the inflammation score, and protected the colonic epithelium
from inflammatory destruction [58]. These studies, together
with the finding that Alk-SMase is downregulated in IBD
[23], support the notion that the decrease of this anti-
inflammatory enzyme may be of relevance in IBD pathogen-
esis and progression.
The excessive cytokine production in IBD appears to
be favored also by the decrease of gangliosides occurring
in this disease. It is recognized that gangliosides in the
apical intestinal surface can influence numerous processes,
includingmicrobial attachment, toxin production, and infec-
tivity of several intestinal pathogens (Figure 3(b)), and
increased ganglioside catabolism occurs in IBD and results
in increased proinflammatory signaling [59]. Intriguingly,
dietary gangliosides emerged as effective elements in reduc-
ing proinflammatory mediators of IBD. Indeed, an induced
ganglioside increase was shown to inhibit both TNF-𝛼 and
IL-1𝛽 proinflammatory signals in rats [27]. Moreover, in a
cultured infant bowel exposed to LPS in hypoxic conditions,
gangliosides were able to reduce both IL-6 and IL-8 produc-
tion [60].
5.3. Cross-Communication of Sphingolipid Messengers with
Eicosanoid and Glycerolipid Signaling. Aberrant production
of bioactive lipids of the eicosanoid family, especially PGs,
was identified to drive chronic inflammation by dysregulating
signaling pathways and/or cellular events and leading to
abnormal immune functions [61]. Eicosanoids, including
PGs, are generated from arachidonic acid, released from
cell membrane phospholipids mainly by phospholipase-A2
(PLA2). Arachidonic acid is then converted to PGs via the
COX pathway. Of the two known COX isoforms (COX-1 and
COX-2), it is COX-2 that is induced during acute or chronic
inflammation [62].
Increased PG production occurs within the gastrointesti-
nal mucosa of patients with IBD, and in experimental models
of IBD [63]. As a consequence, PGs and especially PGE2
act as proinflammatory factors and tool in IBD. Different
studies progressively revealed a key role of sphingolipids in
the modulation of eicosanoid production in inflammatory
processes [64] (Figure 3(a)). Initial studies showed that Cer
and Sph were able to induce PGE2 production [65]. Cer
was shown to enhance cytosolic PLA2 (cPLA2) activity and
PG formation through direct binding to the enzyme [66].
Subsequent studies demonstrated that both C1P and S1P are
involved in the regulation of PGE2 production [67–69], by
acting through different mechanisms. C1P was shown to
activate cPLA2 either directly or by promoting its translo-
cation to intracellular membranes [70–72]. After binding to
different subtypes of its receptors, S1P acts downstream of
Cer, by causing strong and prolonged expression of COX-2
[73], through inducing transcription andmRNA stabilization
[74, 75].
The proinflammatory cytokines IL-1𝛽 and TNF-𝛼 were
shown to regulate both cPLA2𝛼 and COX-2 to promote SM
metabolism and to produce C1P and S1P formation [76].
This signaling pathway starts with A-SMase activation, which
results in the reduction of the SM-mediated inhibition of
cPLA2𝛼. Moreover, the two cytokines activate SphK1 and
ceramide kinase 1, the Cer pool generated by A-SMase finally
promoting both C1P and S1P biosynthesis. In response to
proinflammatory cytokines, C1P and S1P exhibit a significant
synergistic effect on the activation of cPLA2𝛼 and COX-
2, and thus on the production of the key inflammatory
mediators PGE2 [67].
Further support to IBD maintenance derives from the
different catalytic activities exhibited by the Alk-SMase. This
enzyme is able to hydrolyze not only SM, but also other
choline phospholipids, including lysophosphatidylcholine,
with reduction of lysophosphatidic acid, and PAF [15, 77].
Thus, the Alk-SMase reduction of IBD appears to be func-
tional to signaling alterations that potentiate IBD, by reducing
the anti-inflammatory actions exerted by SM and PAF and by
promoting the proinflammatory lysophosphatidic acid.
Although much remains to be understood about these
multiple signaling interactions, the actual knowledge linking
sphingolipids with eicosanoids and glycerolipid messengers
provides a new conceptual view on how alterations of
sphingolipid signaling in IBD act not only as such but also
through regulation of other signalingmolecules.This leads to
increased efficacy in promoting and maintaining the chronic
state of IBD.
6. Sphingolipids: Potential Therapeutic
Benefits/Targets in IBD
The global incidence of IBD is increasing with time [78].
Actually, a step-up strategy is used in the management of
IBD, therapeutic treatments including 5-aminosalicylic acid,
glucocorticoids, immunomodulators, and anti-TNF agents
[79]. Despite advancements in therapy with the introduction
of anti-TNF agents [80, 81], IBD gradually causes serious
effects in terms of morbidity, work disability, and quality of
life [82]. The finding that multiple sphingolipid alterations
are associated with IBD has prompted investigations on the
targeting of sphingolipids as a potential field of therapy for
managing progression and morbidity of this disease.
6.1. Dietary Bioactive Sphingolipids: A Gift from Nourish-
ment. It is generally accepted that dietary components are
involved in immune regulation. The intestinal immune sys-
tem, especially, seems to be directly affected by the digestion
and absorption of dietary compounds and, among them,
dietary lipids have emerged as major determinants of the
intestinal immune responses, mainly after conversion into
lipidmediators [83]. Indeed, as described above, sphingolipid
metabolites act as multifaceted bioactive molecules in IBD,
and different studies demonstrated that dietary complex
sphingolipids, including gangliosides and SM, possess the
potential of effective compounds.
Initial studies on dietary gangliosides demonstrated that
the sialylated GSLs of human milk exert beneficial effects
in infant bowel infections, through enterotoxin-inhibiting
activity and maintenance of the intestinal barrier integrity
[84].Thereafter, it was shown thatmilk gangliosides were able
to inhibit adhesion and suppress the growth of E. coli. In par-
ticular, an infant formula, specifically enriched with GD3 and
GM1 gangliosides, lowered E. coli content and concomitantly
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increased that of bifidobacteria, suggesting a ganglioside role
in the development of intestinal immunity [85]. Furthermore,
Schnabl et al. [60] demonstrated that ganglioside preexpo-
sure to LPS treatment reduces bowel necrosis and endothelin-
1 production in response to LPS, by suppressing infant bowel
production of different proinflammatory mediators, such as
nitric oxide, leukotriene B4, PGE2, hydrogen peroxide, IL-
1𝛽, IL-6, and IL-8. Moreover, very recently, it was reported
that gangliosides, especially GD3, ameliorate intestinal injury
not only by suppressing proinflammatory mediators, but
also by upregulating anti-inflammatory molecules, such as
chemokines and the cytokine IL-10 [86] (Figure 3(b)).
Besides gangliosides, also dietary SM was shown to exert
biomodulatory activities in intestinal inflammation, though
with contrasting results. In the mouse colon, it was observed
that the simultaneous administration of SMandDSS prevents
the increase of myeloperoxidase (MPO) activity, a marker
of neutrophil influx into the inflamed colon [87]. Moreover,
Mazzei et al. [88] recently reported that dietary SM decreased
colonic inflammatory lesions and disease progression inmice
with DSS-induced colitis. On the contrary, two recent papers
by Hausmann’s group showed that, after metabolism to Cer,
dietary SM triggers apoptosis in murine IECs and aggravates
intestinal inflammation in acute DSS-induced colitis and in
IL-10 knockout mice [21, 89]. The reasons of these opposite
findings on dietary SM in intestinal inflammation remain
to be clarified. Although it cannot be excluded that the use
of different mouse strains may be responsible for the anti-
and proinflammatory effects of dietary SM, it appears likely
that the different composition and intestinal hydrolysis of the
administered SM (of milk and egg origin, resp.) play a major
role.
Taken together, these findings suggest that the dietary
assumption of specific types of complex sphingolipids might
be beneficial as preventive/therapeutic strategy against IBD.
6.2. Regulation of Sphingolipid Metabolites by Dietary Mate-
rials. In addition to dietary sphingolipids, the assumption of
dietary compounds able tomodify the intestinal sphingolipid
metabolism has emerged as an intriguing possibility to
influence the IBD status.
It has been demonstrated that a diet enriched with fibers
and fats is able to influence the expression of both intestinal
SMases and CDases. Psyllium, a water soluble fiber partly
digested by bacterial flora, increased the activity of Alk-
SMase and decreased that of A-SMase and N-CDase allevi-
ating inflammation, whereas a high-fat diet exerted opposite
effects [90]. Moreover, in IL-10 KO mice with colitis, it
was demonstrated that the VSL#3 probiotic upregulates Alk-
SMase activity, suggesting its potential as anti-inflammatory
agent [91].
Luteolin, a tetrahydroxyflavone present in a variety of
vegetables, fruits, and medicinal herbs, has been shown
to function as an antioxidant, anti-inflammatory, and anti-
cancer agent [92]. Very recently, we reported that dietary lute-
olin is able to unbalance the sphingolipid rheostat by inhibit-
ing both S1P biosynthesis and Cer traffic in colon cancer cells
[93], suggesting its dietary introduction/supplementation as
a potential strategy to improve inflammation in colorectal
cancer. These findings prompt further investigations on
dietary molecules able to modulate sphingolipid metabolism
as anti-IBD foods.
6.3. Targeting Sphingolipids: A Potential Anti-IBD Strategy.
The discovery of alterations of sphingolipid metabolism
and signaling in IBD paved the way for the discovery of
pharmacological approaches to prevent/treat this disease.
Up to now, several compounds have been discovered to
manipulate the SM cycle and S1P metabolism/receptors, and
these were evaluated for their potential therapeutic benefit
generally in inflammation, and especially in IBD.
So far, the most high-profile drug that improves inflam-
mation via S1P receptor (S1PR) modulation and is assessed
in vivo is the fungal metabolite fingolimod (FTY720). Dif-
ferently from typical immunosuppressive drugs, its mode of
action is not via inhibition of T-cell function, but via down-
regulation of S1P1 on lymphocytes, leading to the inhibition
of their egress from the lymph nodes [94]. As a consequence,
FTY720 reduces the number of T-cells circulating between
lymph nodes and the peripheral site of tissue inflammation.
In agreement with this action, Mizushima et al. [95] demon-
strated the efficacy of FTY720 in decreasing the severity
of spontaneous colitis in the IL-10-deficient mouse model.
FTY720 induced accelerated homing and sequestration of T-
cells into Peyer’s patches andmesenteric lymph nodes, result-
ing in a reduction of CD4+ T lymphocytes into the lamina
propria [95]. An additional study provided new evidence on
the immunosuppressive properties of FTY720. In particular,
in a chemically induced mouse model of colitis, FTY720
treatment markedly reduced the severity of intestinal inflam-
mation [96].This therapeutic effect of FTY720was associated
with downregulation of different proinflammatory cytokines,
paralleled by a functional activity of CD4+CD25+ regulatory
T-cells and prominent upregulation of anti-inflammatory
mediators [96].
The finding that S1P1 modulation was the major mecha-
nism of FTY720’s efficacy prompted the search for second-
generation compounds, with high selectivity to S1P1, and
lower clinical adverse events (linked to its agonistic activity
to S1P3), such as symptomatic bradycardia [97]. Among new
drugs, KRP-203, S1P1/4/5 agonist prodrug with a molecular
structure resembling FTY720 with high selectivity to S1P1,
was developed for immunomodulation in autoimmune dis-
eases and organ transplantation [98]. In the IL-10-deficient
mouse, a validated model of human IBD, KRP-203 regulated
not only T-cell response but also B-cell one [99]. Its treatment
resulted in a significant reduction in the severity of colitis
and in the number of CD4(+) T-cell and B220(+) B-cell
subpopulations and T-helper 1 (Th1) cytokine production in
colonic mucosa, a histopathological hallmark of IBD [99].
Thus, the use of KRP-203 emerged as an option to be tapped
into effective immunointervention in IBD.
W-061, a novel and potent S1P1 agonist, structurally
different from Sph and active in vivo without undergoing
phosphorylation, showed effectiveness for alleviating mul-
tiple aspects of chronic intestinal inflammation in DSS-
induced colitis, such as preventing mucosal thickness and
mucin depletion induced by DSS. The novel effect attributed
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exclusively to W-0671 as S1PR agonist is the suppression of
Th17 and Th1 increase in the lamina propria, by the seques-
tration of these cells into secondary lymphoid tissues [100].
It has been recently demonstrated that SEW 2871, another
selective S1P1 agonist, ameliorates colitis in IL-10-deficient
mice, by reducing proinflammatory cytokines production
and promoting the expression of TJ typical proteins [101].
A further, highly specific S1P1 agonist, named RPC 1063,
has been successfully tested in animal models of IBD and is
currently being used as an oral therapeutic in phase II clinical
trials of UC [102].
Besides S1PR antagonists, other drugs exhibiting a
promising therapeutic benefit in IBD are those targeting the
S1P axis and acting as SphK inhibitors. Different studies
demonstrated that the orally available inhibitors of SphKs,
ABC747080 and ABC294640, are effective in inhibiting the
severity of colitis [29, 103, 104].This protection is likely due to
the significant decrease, induced by the inhibitors, of a broad
spectrum of inflammatory mediators, such as TNF-𝛼, COX-
2, IL-1𝛽, IFN-𝛾, MPO, and IL-6, including S1P. Moreover,
SphK inhibitors were able to attenuate the effects of TNF-𝛼-
induced increase in the expression of the adhesion proteins
physiologically involved in leukocyte recruitment.
Of notice, in both acute and chronic models of UC, it has
been reported that SphK inhibitors and Dipentum, an FDA-
approved anticolitis drug, exhibit similar effects in reducing
inflammation extent and severity, with the best results in a
combinatory delivery [103]. These results are encouraging
and shed light on a possible combination of SphK inhibitors
and anti-IBD drugs for further clinical IBD improvement.
Overall, it emerged that SphK is an excellent target for the
development of new anti-IBD drugs.
Additional studies investigated the SM cycle as therapeu-
tic target in IBD. By using SMA-7, an inhibitor of A-SMase
and N-SMase, it was found that, besides suppressing Cer
production, it was effective in inhibiting NF-𝜅B activation
and inflammatory cytokine release from macrophages [55].
In murine models of colitis, the oral administration of SMA-
7 induced a significant decrease in the NF-𝜅B-dependent
cytokine levels and reduced alterations and damage in the
colonic mucosal layer [55]. Whether N- and A-SMases play a
different role in the regulation the IBD inflammation and the
contribution of Cer inhibition and/or S1P reduction as key
effectors of the SMA-7 effect remain to be clarified.
Finally, also glycosylated sphingolipids recently emerged
as compounds of potential benefit in IBD. In particular,
cerebroside D, a glycoceramide compound from fungal cul-
ture, was presented for its immunosuppressive activity and
efficiency in improving DSS-induced colitis in mice [105].
Its anti-inflammatory mechanism involves multiple effects
against activated T-cells in colon, such as regulation of the
cytokine profile and apoptosis induction in activated T-cell
effectors. Thus, by interfering with na¨ıve T-cell activation,
cerebroside D appears to be of relevance for IBD manage-
ment.
7. Closing Remarks
Taken together, a huge and increasing volume of experimen-
tal evidence points to the importance of sphingolipids/sphin-
goids molecules, and their enzymes, in IBD development and
fate. However, at present, several gaps in our knowledge and
many questions need to be understood better. Among them,
more knowledge is required on the mechanisms underlying
the in vivo digestion/absorption of sphingolipids in the gas-
trointestinal system, as well as on the effective concentrations
shifting them from food components to dietary bioactive
nutrients.The influence of specific lipids, and theirmodifying
enzymes, on intestinal lipid-barrier control is an area of great
promise that needs to be investigated further to develop novel
treatment strategies that strengthen the intestinal barrier and
possibly halt, or at least slow down, the initial alterations
leading to IBD. Itwill be also of relevance to better understand
the multifaceted role of sphingolipid molecules in IBD and
their subcellular localization, as well as cross talk with other
intestinal factors involved in this disease. The potential of
diet components in changing the sphingolipid amount and
pattern in the gut remains an open question. In the “future
food” field, it is a hard challenge to find out new compounds
targeting sphingolipid metabolism and able to self-actualize,
or to combine with other drugs, for effective IBD treatment
with minimal side effects. Based on the preclinical findings
of the anti-IBD potential of sphingolipid, hard work remains
to establish their efficacy and to upgrade and improve
treatments to clinical endpoints. Deeper understanding of the
proper role of sphingolipids and their enzymes in controlling
the intestinal properties and in promoting the pathogenesis
and progression of IBD will generate new perspectives in the
development of “sphingolipid-centered” therapeutic strate-
gies that control the onset and perpetuation of this disabling
inflammation.
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